AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23949563 — intervention group
Group type: COMPARATOR
Intervention: Standard-volume split-dose polyethylene glycol with standard diet (SV-PEG with SD)
Number of subjects: 197
Study 23272429 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 100
Study 23272429 — intervention group
Group type: COMPARATOR
Intervention: Dilatation and Curettage (DNC)
Number of subjects: 100
Study 19413144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - sleep education, stimulus control, and time‐in‐bed restrictions; 20 patients with primary insomnia and 21 with comorbid insomnia
Number of subjects: 81
Study 19413144 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene (SH) - education about aspects of lifestyle and the bedroom environment that affect sleep; 20 patients with primary insomnia and 20 with comorbid insomnia
Number of subjects: 81
Study 18000777 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 646
Study 18000777 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 646
Study 18000777 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 646
Study 15151490 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT) with non-invasive ventilation
Number of subjects: 34
Study 15151490 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-invasive ventilation alone)
Number of subjects: 34
Study 11713064 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fluorometholone (FML) six times daily for 4 weeks (group 1)
Number of subjects: 31
Study 11713064 — intervention group
Group type: COMPARATOR
Intervention: Topical fluorometholone (FML) three times daily for 4 weeks (group 2)
Number of subjects: 31
Study 9334554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of methylphenidate twice per day
Number of subjects: 31
Study 9334554 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg of methylphenidate twice per day
Number of subjects: 31
Study 9334554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8390511 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 24
Study 8390511 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 24
Study 3720365 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine at regular intervals
Number of subjects: 20
Study 3720365 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous nicomorphine on demand
Number of subjects: 20
Study 30025941 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Scheduling Program (CSP)
Number of subjects: 124
Study 30025941 — intervention group
Group type: COMPARATOR
Intervention: Standard e-mail/phone scheduling
Number of subjects: 124
Study 28158197 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRT with treadmill‐plus
Number of subjects: 24
Study 28158197 — intervention group
Group type: EXPERIMENTAL
Intervention: MIRT with Lokomat®
Number of subjects: 24
Study 25970759 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical haemoglobin spray
Number of subjects: 72
Study 25970759 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 72
Study 22999321 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pulmonary artery systolic pressures (PASP)
Number of subjects: 174
Study 22999321 — intervention group
Group type: COMPARATOR
Intervention: Post-operative AF patients
Number of subjects: 174
Study 21504072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixim 400 mg/day for 5 days
Number of subjects: 104
Study 21504072 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 250‐500 mg twice a day for 5 days
Number of subjects: 104
Study 19352378 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut group (30 g per day walnuts)
Number of subjects: 50
Study 19352378 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut group
Number of subjects: 50
Study 19352378 — intervention group
Group type: COMPARATOR
Intervention: Control group (low-fat dietary advice)
Number of subjects: 50
Study 19352378 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 16917901 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive assessment method for energy expenditure (EE) based on regression modeling using heart rate (HR) and other variables
Number of subjects: 74
Study 16917901 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive assessment method for energy expenditure (EE)
Number of subjects: 74
Study 15253118 — intervention group
Group type: EXPERIMENTAL
Intervention: Bod Pod
Number of subjects: 160
Study 15253118 — intervention group
Group type: COMPARATOR
Intervention: DXA
Number of subjects: 160
Study 15253118 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of Bod Pod and DXA
Number of subjects: 160
Study 11751712 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-sensitive subjects
Number of subjects: 28
Study 11751712 — intervention group
Group type: COMPARATOR
Intervention: Salt-resistant subjects
Number of subjects: 28
Study 9591737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 0.4 ng x kg(‐1) x min(‐1)
Number of subjects: 5
Study 9591737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon infusion at 1.2 ng x kg(‐1) x min(‐1)
Number of subjects: 5
Study 9591737 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher rate of glucagon infusion (1.2 ng x kg(‐1) x min(‐1))
Number of subjects: 5
Study 9591737 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon excess
Number of subjects: 5
Study 7872910 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Training (WT)
Number of subjects: 14
Study 7872910 — intervention group
Group type: COMPARATOR
Intervention: Non-Weight-Trained Control (NWT)
Number of subjects: 14
Study 3061416 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (AZT)
Number of subjects: 0
Study 3061416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29960156 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil/LCT (OO/LCT)
Number of subjects: 67
Study 29960156 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (LCT)
Number of subjects: 67
Study 29960156 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium/long-chain triglycerides
Number of subjects: 67
Study 29960156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mix of LCT/MCT/OO/fish oil
Number of subjects: 67
Study 26965560 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (solifenacin 5 mg + mirabegron 50 mg)
Number of subjects: 2174
Study 26965560 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 5 mg
Number of subjects: 2174
Study 26965560 — intervention group
Group type: COMPARATOR
Intervention: Solifenacin 10 mg
Number of subjects: 2174
Study 25640020 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 76
Study 25640020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23084955 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 131
Study 23084955 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy with adjunctive manual therapy (ET+MT)
Number of subjects: 131
Study 23084955 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 131
Study 21199294 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 397
Study 21199294 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 397
Study 18040663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 92
Study 18040663 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 92
Study 16825690 — intervention group
Group type: EXPERIMENTAL
Intervention: 416 microg [6S]-5-MTHF/d
Number of subjects: 144
Study 16825690 — intervention group
Group type: COMPARATOR
Intervention: 400 microg folic acid/d
Number of subjects: 144
Study 16825690 — intervention group
Group type: EXPERIMENTAL
Intervention: 208 microg [6S]-5-MTHF/d
Number of subjects: 144
Study 16825690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 14506195 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re-labeled BIWA 4 (bivatuzumab) at doses of 20, 30, 40, 50, and 60 mCi/m2
Number of subjects: 20
Study 14506195 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re-labeled BIWA 4 (bivatuzumab) at 60 mCi/m2
Number of subjects: 20
Study 14506195 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re-labeled BIWA 4 (bivatuzumab)
Number of subjects: 20
Study 10699324 — intervention group
Group type: COMPARATOR
Intervention: cpts 248/404 RSV vaccine
Number of subjects: 120
Study 10699324 — intervention group
Group type: EXPERIMENTAL
Intervention: sequential immunization
Number of subjects: 120
Study 10699324 — intervention group
Group type: EXPERIMENTAL
Intervention: simultaneous immunization
Number of subjects: 120
Study 8867548 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinued low dose methotrexate (MTX) prior to and during surgery (Group 1, n = 19)
Number of subjects: 32
Study 8867548 — intervention group
Group type: COMPARATOR
Intervention: Continued low dose methotrexate (MTX) throughout the perioperative period (Group 2, n = 13)
Number of subjects: 32
Study 2258342 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of pefloxacin 800 mg
Number of subjects: 222
Study 2258342 — intervention group
Group type: COMPARATOR
Intervention: Five-day treatment with norfloxacin 400 mg twice daily
Number of subjects: 222
Study 6987112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV by intramuscular injection and topically
Number of subjects: 144
Study 6987112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifamycin SV by injection only
Number of subjects: 144
Study 6987112 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment used at the particular centre
Number of subjects: 144
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC cessation
Number of subjects: 176
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC cessation in paraplegic participants
Number of subjects: 176
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: Years since SCI
Number of subjects: 176
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥4 urinary tract infections (UTIs) in a year
Number of subjects: 176
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetraplegia
Number of subjects: 176
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC cessation in tetraplegics
Number of subjects: 176
Study 31578784 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent UTIs
Number of subjects: 176
Study 30024217 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic Growth Inventory (PTGI)
Number of subjects: 613
Study 30024217 — intervention group
Group type: COMPARATOR
Intervention: Stress Related Growth Scale-Revised (SRGS-R)
Number of subjects: 613
Study 26656728 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the right dlPFC
Number of subjects: 0
Study 26656728 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS over the right dlPFC
Number of subjects: 0
Study 26656728 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 25316715 — intervention group
Group type: EXPERIMENTAL
Intervention: t:slim Insulin Pump
Number of subjects: 72
Study 25316715 — intervention group
Group type: COMPARATOR
Intervention: Revel Insulin Pump
Number of subjects: 72
Study 23171880 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma sICAM-1 level (quartile 4 vs. quartile 1)
Number of subjects: 1536
Study 23171880 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma hs-CRP level (quartile 4 vs. quartile 1)
Number of subjects: 1536
Study 21607987 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 427
Study 21607987 — intervention group
Group type: COMPARATOR
Intervention: Dyslipidemia
Number of subjects: 427
Study 19489765 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1.6 g eicosapentaenoic acid and 1.1 g docosahexaenoic acid)
Number of subjects: 145
Study 19489765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 16957638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone 300 mg daily for 3 days, tapered over 1 week
Number of subjects: 40
Study 16957638 — intervention group
Group type: COMPARATOR
Intervention: Intravenous metoclopramide 10 mg 3 times daily for 1 week
Number of subjects: 40
Study 15327918 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC; -110 degrees C) for 2 min, repeated three times per week for 3 months (13 weeks)
Number of subjects: 20
Study 15327918 — intervention group
Group type: COMPARATOR
Intervention: Winter swimming (WS) in ice-cold water for 20 s, repeated three times per week for 3 months (13 weeks)
Number of subjects: 20
Study 10753831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF (2.5 or 5 microg/kg/day)
Number of subjects: 57
Study 10753831 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 57
Study 10753831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 9525336 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (850 mg/day)
Number of subjects: 369
Study 9525336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary calcium intake
Number of subjects: 369
Study 9525336 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR gene polymorphisms
Number of subjects: 369
Study 8205268 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (50 mg/day)
Number of subjects: 29133
Study 8205268 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (20 mg/day)
Number of subjects: 29133
Study 8205268 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 29133
Study 3330661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physician antismoking advice)
Number of subjects: 258
Study 3330661 — intervention group
Group type: COMPARATOR
Intervention: Control group (customary care practices)
Number of subjects: 258
Study 28929400 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 276
Study 28929400 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 276
Study 26310941 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin Qigong (BQG)
Number of subjects: 100
Study 26310941 — intervention group
Group type: COMPARATOR
Intervention: Control group (daily walking for 30 min)
Number of subjects: 100
Study 24256336 — intervention group
Group type: EXPERIMENTAL
Intervention: multi‐component intervention for smoking cessation and cardiovascular disease risk reduction
Number of subjects: 200
Study 24256336 — intervention group
Group type: EXPERIMENTAL
Intervention: smokers with psychosis
Number of subjects: 200
Study 24256336 — intervention group
Group type: EXPERIMENTAL
Intervention: smokers diagnosed with psychosis
Number of subjects: 200
Study 24250874 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (300-600 mg/day)
Number of subjects: 57
Study 24250874 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (450-900 mg/day)
Number of subjects: 57
Study 24250874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 21353105 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 1000 mg q6h
Number of subjects: 244
Study 21353105 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen 650 mg q4h
Number of subjects: 244
Study 21353105 — intervention group
Group type: COMPARATOR
Intervention: IV placebo 100 mL q6h
Number of subjects: 244
Study 21353105 — intervention group
Group type: COMPARATOR
Intervention: IV placebo 65 mL q4h
Number of subjects: 244
Study 19128627 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental guide and treatment algorithm
Number of subjects: 80
Study 19128627 — intervention group
Group type: COMPARATOR
Intervention: Standard care with acetaminophen (15 mg/kg) and morphine (0.3 mg/kg)
Number of subjects: 80
Study 16179595 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 10
Study 16179595 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg)
Number of subjects: 10
Study 16179595 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 10
Study 16179595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16179595 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 10
Study 16179595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Number of subjects: 10
Study 14509502 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective hepatic vascular exclusion (SHVE)
Number of subjects: 110
Study 14509502 — intervention group
Group type: COMPARATOR
Intervention: Pringle maneuver
Number of subjects: 110
Study 11219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Centroid method with floating reference
Number of subjects: 80
Study 11219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-sectional fractional area change (FAC)
Number of subjects: 80
Study 11219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental FAC by fixed reference
Number of subjects: 80
Study 11219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental FACs
Number of subjects: 80
Study 11219597 — intervention group
Group type: EXPERIMENTAL
Intervention: Centroid method with floating reference and cross-sectional FACs
Number of subjects: 80
Study 8851908 — intervention group
Group type: EXPERIMENTAL
Intervention: Convective cooling of the hand (60 min) at air temperatures of 0, 4, 10, and 16 degrees C
Number of subjects: 28
Study 8851908 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact cooling of the finger pad (5 min) with an aluminum cube at temperatures of -7, 0, and 7 degrees C
Number of subjects: 28
Study 1543449 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg/d)
Number of subjects: 3711
Study 1543449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3711
Study 2860182 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rinsing with povidone-iodine
Number of subjects: 17
Study 2860182 — intervention group
Group type: EXPERIMENTAL
Intervention: Open abdominal wall with pancreatic space packed
Number of subjects: 17
Study 2860182 — intervention group
Group type: COMPARATOR
Intervention: Conservative closure of the abdominal wall
Number of subjects: 17
Study 30403954 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 2 g
Number of subjects: 179
Study 30403954 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin 3 g
Number of subjects: 179
Study 30403954 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 500 mg
Number of subjects: 179
Study 29231521 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy, applied once every two weeks for a total of 3 times
Number of subjects: 60
Study 29231521 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture, applied once every day for 6 weeks
Number of subjects: 60
Study 24533515 — intervention group
Group type: EXPERIMENTAL
Intervention: Webinar AFIX consultation
Number of subjects: 61
Study 24533515 — intervention group
Group type: COMPARATOR
Intervention: In-person AFIX consultation
Number of subjects: 61
Study 22958105 — intervention group
Group type: EXPERIMENTAL
Intervention: New warning label
Number of subjects: 0
Study 22958105 — intervention group
Group type: COMPARATOR
Intervention: Old warning label
Number of subjects: 0
Study 20670400 — intervention group
Group type: EXPERIMENTAL
Intervention: C282Y-carrier status
Number of subjects: 667
Study 20670400 — intervention group
Group type: EXPERIMENTAL
Intervention: H63D-carrier status
Number of subjects: 667
Study 20670400 — intervention group
Group type: EXPERIMENTAL
Intervention: S65C-carrier status
Number of subjects: 667
Study 20670400 — intervention group
Group type: EXPERIMENTAL
Intervention: HFE homozygous or compound heterozygous carriers
Number of subjects: 667
Study 17896116 — intervention group
Group type: EXPERIMENTAL
Intervention: Total-etching with 36% phosphoric acid followed by an acetone-based adhesive (Prime&Bond NT)
Number of subjects: 240
Study 17896116 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etch adhesive system (Xeno III)
Number of subjects: 240
Study 17896116 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone-based adhesive (Prime&Bond NT) without prior acid conditioning
Number of subjects: 240
Study 17896116 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 240
Study 15747239 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 17-65 years
Number of subjects: 144485
Study 15747239 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >= 65 years
Number of subjects: 144485
Study 15747239 — intervention group
Group type: COMPARATOR
Intervention: Derivation cohort
Number of subjects: 144485
Study 15747239 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort
Number of subjects: 144485
Study 12554608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanamide (200 mg daily)
Number of subjects: 26
Study 12554608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 12554608 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanamide
Number of subjects: 26
Study 11029348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA)
Number of subjects: 24
Study 11029348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8800992 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine (500 micrograms delivered over 72 h)
Number of subjects: 16
Study 8800992 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 16
Study 1738571 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (MT)
Number of subjects: 35
Study 1738571 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 35
Study 1738571 — intervention group
Group type: COMPARATOR
Intervention: Both agents (AT and MT)
Number of subjects: 35